Warfarin pharmacogenetics in patients with heart valve replacement

Bezci, Kivanc; Cevik, Mehtap; Akdeniz, Cansu; Canbolat, Ismail; Yurdakul, Selen; SÜNBÜL, MURAT; Atas, Halil; Cagatay, Penbe; Ciftci, Cavlan; KARAALP, ATİLA; SÜSLEYİCİ, BELGİN

doi:10.1016/j.genrep.2020.100769

Warfarin pharmacogenetics in patients with heart valve replacement

Bezci K., Cevik M., Akdeniz C. S., Canbolat I. P., Yurdakul S., SÜNBÜL M., ...Daha Fazla

GENE REPORTS, cilt.20, 2020 (ESCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.genrep.2020.100769
Dergi Adı: GENE REPORTS
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, BIOSIS, EMBASE
Anahtar Kelimeler: Warfarin, CYP2C9, Heart valve replacement, Polymorphism, REDUCTASE COMPLEX SUBUNIT-1, VITAMIN-K ANTAGONISTS, BLEEDING COMPLICATIONS, GENE POLYMORPHISMS, ANTICOAGULANT-THERAPY, CYP2C9 POLYMORPHISM, ATRIAL-FIBRILLATION, VKORC1, ASSOCIATION, VARIABILITY
Marmara Üniversitesi Adresli: Evet

Özet

Background: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin.